STI571: a gene product-targeted therapy for leukemia.

M. J. Mauro, B. J. Druker

Research output: Contribution to journalReview article

32 Scopus citations

Abstract

Chronic myelogenous leukemia (CML) is a clonal hematopoietic stem-cell disorder characterized by the (9:22) translocation and resultant production of the constitutively activated bcr-abl tyrosine kinase. Characterized clinically by marked myeloid proliferation, it invariably terminates in an acute leukemia. Conventional therapeutic options include interferon-based regimens and stem-cell transplantation, with stem-cell transplantation being the only curative therapy. Through rational drug development, STI571, a bcr-abl tyrosine kinase inhibitor, has emerged as a paradigm for gene product-targeted therapy, offering new hope for expanded treatment options for patients with CML.

Original languageEnglish (US)
Pages (from-to)223-227
Number of pages5
JournalCurrent oncology reports
Volume3
Issue number3
DOIs
StatePublished - May 2001

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'STI571: a gene product-targeted therapy for leukemia.'. Together they form a unique fingerprint.

  • Cite this